Pre-existing humoral immunity and CD4+ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination

Shen, Ching‐Fen; Fu, Yi-Chen; Ho, Tzong Shiann; Chen, Po‐Lin; Lee, Nan-Yao; Tsai, Bo‐Yang; Tsai, Pei-Jane; Ko, Wen–Chien; Liu, Ching-Chuan; Cheng, Chao‐Min; Shieh, Chi‐Chang

doi:10.1016/j.clim.2023.109342

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Preprint1

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

QuantiFERON SARS-CoV-2 assay for the evaluation of cellular immunity after immunization with mRNA SARS-CoV-2 vaccines: a systematic review and meta-analysis

Dourdouna,

Kourlaba,

Michos

2024

Immunol Res

View full text Add to dashboard Cite

QuantiFERON SARS-CoV-2 assay for the evaluation of cellular immunity after immunization with mRNA SARS-CoV-2 vaccines: a systematic review and meta-analysis

Dourdouna,

Kourlaba,

Michos

2024

Immunol Res

View full text Add to dashboard Cite

SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern

Hojo-Souza,

de Castro,

Rivelli

et al. 2024

Vaccine

View full text Add to dashboard Cite

QuantiFERON SARS-CoV-2 assay for the evaluation of cellular immunity after immunization with mRNA SARS-CoV-2 vaccines: A Systematic Review and Meta-Analysis

Dourdouna,

Kourlaba,

Michos

2024

Preprint

View full text Add to dashboard Cite

A systematic review and meta-analysis was performed to evaluate the virus-specific T-cell response after COVID-19 mRNA vaccination, using the QuantiFERON-SARS-CoV-2 Interferon-γ Release Assay. A search was conducted (June 8, 2023) in the PUBMED, SCOPUS and medRxiv databases, to identify studies reporting the QuantiFERON-SARS-CoV-2 [Starter (two Antigen tubes) or Starter+Extended Pack (three Antigen tubes), cut-off³0.15IU/mL] Positivity Rate (PR) in immunocompetent adults, following the administration of two or three COVID-19 mRNA vaccine doses. Study quality was evaluated with the Critical Appraisal Skills Program Tool. A meta-analysis was conducted using a Random-Effects model. Heterogeneity and publication bias were assessed. Eleven eligible studies (with 5-75 vaccinated immunocompetent participants) were identified. For COVID-19-naive participants, £3 months after the second dose, the pooled PR (Random-Effects model) was 81 [95% Confidence Interval (95%CI):71-92]%. Comparing the Starter vs. the Starter+Extended Pack, a significant difference in PRs was detected (79.3% vs. 92.2%, p-value=0.039). At 3-6 and >6 months after the second dose and at ³3 months after the third dose, the pooled PRs were 59(95%CI:45-72)%, 79(95%CI:66-92)% and 66(95%CI:50-82)%, respectively. For convalescent participants, ³6 months after the third dose, the pooled PR was 81(95%CI:67-92)%. In conclusion, following the second or third COVID-19 mRNA vaccine, QuantiFERON-SARS-CoV-2 detected positive responses in a certain percentage of the vaccinees. This detection was higher when the Starter+Extended Pack was used. Possible explanations for the assay’s negative results in a subset of the participants could be: waning immunity, reduced sensitivity compared to other T-cell assays or lack of T-cell response induction in some vaccinees. (PROSPERO Registration Number:CRD42023431315)

show abstract

Pre-existing humoral immunity and CD4+ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination

Cited by 4 publications

References 36 publications

QuantiFERON SARS-CoV-2 assay for the evaluation of cellular immunity after immunization with mRNA SARS-CoV-2 vaccines: a systematic review and meta-analysis

QuantiFERON SARS-CoV-2 assay for the evaluation of cellular immunity after immunization with mRNA SARS-CoV-2 vaccines: a systematic review and meta-analysis

SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern

QuantiFERON SARS-CoV-2 assay for the evaluation of cellular immunity after immunization with mRNA SARS-CoV-2 vaccines: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About